zPREDICTA, a provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics, has entered into a strategic collaboration with LabCorp. The agreement will support the adoption of zPREDICTA’s proprietary 3D cell culture platform for preclinical testing and research studies in the biopharmaceutical industry.
 
The collaboration combines zPREDICTA’s strengths in the development of clinically relevant 3D cell culture models with LabCorp’s strengths in drug development and precision medicine. Since its founding in 2014, zPREDICTA has provided customized tumor-specific 3D cell culture models and in vitro testing services to leading global biotechnology and pharmaceutical companies. The collaboration with LabCorp is an important next step in the evolution of zPREDICTA’s business.
 
“We are very pleased to enter into this strategic collaboration with LabCorp, and we look forward to working together to accelerate the adoption of our 3D cell culture platform across the biopharmaceutical industry,” said Julia Kirshner, founder and chief executive officer, zPREDICTA. “LabCorp is one of the world’s leading life science companies, and its drug development business, Covance, is one of the leading end-to-end development partners for the biopharmaceutical industry. With this strategic relationship, we are well-positioned to offer our cell culture technology to a much larger customer base and also to expand the number of cell culture models that we offer.”
 
Steve Anderson, chief scientific officer, Covance, said, “Given our focus on precision medicine, particularly in the area of oncology, we are looking forward to working with zPREDICTA to develop and commercialize tumor-specific preclinical models based on its 3D cell culture technology. Covance continues to invest in innovations that improve drug development. We believe the zPREDICTA 3D in vitro models offer a more predictable method for early evaluation of responses to immuno-oncology therapies.”